A prospective comparison of epoetin beta pegol and darbepoetin alpha in the variability of blood pressure in pre-dialysis chronic kidney disease (CKD)

INTERVENTION: Epoetin beta pegol groups: Patients are initially given 25‐250 micrograms of epoetin beta pegol once a month for 48 weeks. darbepoetin alpha groups: Patients are initially given 60‐180 micrograms of darbepoetin alpha once a month for 48 weeks. CONDITION: Chronic kidney disease anemia PRIMARY OUTCOME: Blood pressure variability(clinical BP, pulse rate, central blood pressure, PWV, pulse pressure, CAVI, ABPM) SECONDARY OUTCOME: 1.Cardio vascular events; 2.Hemoglobin; 3.Estimated GFR; 4.Serum creatinine; 5.Proteinuria; 6.Dialysis initiation; 7.Renal transplantation; 8.mortality INCLUSION CRITERIA: 1.Pre‐dialysis chronic kidney disease 2.20 years and over 3.Above 40 kg, below 80 kg 4.estimated GFR<60 ml/min/1.73m2 (within 12 weeks) 5.TSAT=>20% (within 4 weeks) 6.Hemoglobin level<=11.0g/dL (within 8 weeks) 7.Patients who have not recieved rHuEPO within 12 weeks